newsfilter
← Latest News
PR Newswire·

Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

-Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022- -Company completes $60.0 million private placement- RED BANK, N.J., Aug. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical